行业分析 |
|
|
|
|
全球双特异性抗体药物研发格局分析* |
毛开云,李荣,李丹丹,赵若春,范月蕾,江洪波() |
中国科学院上海生命科学信息中心 中国科学院上海营养与健康研究所 上海 200031 |
|
Analysis of the Current Status of Global Bispecific Antibody Development |
MAO Kai-yun,LI Rong,LI Dan-dan,ZHAO Ruo-chun,FAN Yue-lei,JIANG Hong-bo() |
Shanghai Information Center for Life Sciences, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031,China |
引用本文:
毛开云,李荣,李丹丹,赵若春,范月蕾,江洪波. 全球双特异性抗体药物研发格局分析*[J]. 中国生物工程杂志, 2021, 41(11): 110-118.
MAO Kai-yun,LI Rong,LI Dan-dan,ZHAO Ruo-chun,FAN Yue-lei,JIANG Hong-bo. Analysis of the Current Status of Global Bispecific Antibody Development. China Biotechnology, 2021, 41(11): 110-118.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2107065
或
https://manu60.magtech.com.cn/biotech/CN/Y2021/V41/I11/110
|
[1] |
Nisonoff A, Wissler F C, Lipman L N. Properties of the major component of a peptic digest of rabbit antibody. Science, 1960, 132(3441):1770-1771.
doi: 10.1126/science.132.3441.1770
|
[2] |
Labrijn A F, Janmaat M L, Reichert J M, et al. Bispecific antibodies: a mechanistic review of the pipeline. Nature Reviews Drug Discovery, 2019, 18(8):585-608.
doi: 10.1038/s41573-019-0028-1
pmid: 31175342
|
[3] |
Nie S W, Wang Z Z, Moscoso-Castro M, et al. Biology drives the discovery of bispecific antibodies as innovative therapeutics. Antibody Therapeutics, 2020, 3(1):18-62.
doi: 10.1093/abt/tbaa003
|
[4] |
Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an fc enhanced EGFR/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis. Molecular Cancer Therapeutics, 2020, 19(10):2044-2056.
doi: 10.1158/1535-7163.MCT-20-0071
|
[5] |
Jovčevska I, Muyldermans S. The therapeutic potential of nanobodies. BioDrugs, 2020, 34(1):11-26.
doi: 10.1007/s40259-019-00392-z
pmid: 31686399
|
[6] |
Hussain R M, O’Leary P, Eichenbaum D A, et al. Faricimab. Anti-Ang-2/anti-VEGF-A bispecific antibody, Treatment of diabetic macular edema, Treatment of wet age-related macular degeneration. Drugs of the Future, 2020, 45(7):449.
doi: 10.1358/dof.2020.45.7.3127028
|
[7] |
van der Horst H J, de Jonge A V, Hiemstra I H, et al. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer Journal, 2021, 11:38.
doi: 10.1038/s41408-021-00430-6
|
[8] |
Patriarca A, Gaidano G. Investigational drugs for the treatment of diffuse large B-cell lymphoma. Expert Opinion on Investigational Drugs, 2021, 30(1):25-38.
doi: 10.1080/13543784.2021.1855140
pmid: 33295827
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|